Company Profile
Milestone Pharmaceuticals Inc. Stock Price, News & Analysis
- Ticker:
- MIST
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada
Stock performance
1.18 USD (+3.06%)
Close
Last updated: August 6, 2026
164M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, MIST closed up 3.06% at $1.18. No new same-company headline was identified in the current news window.
Company overview
Self-Administered Cardiac Rescue Therapy
Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions.
CARDAMYST
CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal supraventricular tachycardia to sinus rhythm.
Atrial Fibrillation Expansion
Milestone is extending etripamil into atrial fibrillation with rapid ventricular rate, where an at-home treatment could reduce emergency intervention.
International Development
The European Medicines Agency is reviewing etripamil for PSVT under the proposed brand TACHYMIST.
Future catalysts
Patient enrollment in the Phase 3 atrial fibrillation with rapid ventricular rate registration trial is expected to begin in the second half of 2026.
The EMA review of the marketing authorization application for etripamil in PSVT is ongoing.
Recent news
- 01
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
Source: Milestone Pharmaceuticals Inc.
- 02
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Milestone Pharmaceuticals Inc.
- 03
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Source: Milestone Pharmaceuticals Inc.
- 04
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
Source: Milestone Pharmaceuticals Inc.
- 05
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
Source: Milestone Pharmaceuticals Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Milestone Pharmaceuticals Inc. (MIST)?
Milestone Pharmaceuticals Inc. (MIST) most recently closed at 1.18 USD, a +3.06% move versus the previous session.
What is the market cap of Milestone Pharmaceuticals Inc. (MIST)?
Milestone Pharmaceuticals Inc. currently has a market capitalization of 164M USD on BioPharmSignal.
What does Milestone Pharmaceuticals Inc. do?
Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal supraventricular tachycardia to sinus rhythm. Atrial Fibrillation Expansion Milestone is...
On which exchange is MIST stock listed?
Milestone Pharmaceuticals Inc. (MIST) is associated with NASDAQ, Canada, Biopharma.
What is Self-Administered?
Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions.
Which conditions is Milestone Pharmaceuticals Inc. targeting with Self-Administered?
Milestone Pharmaceuticals Inc. is associated with cardiovascular disease based on its company overview and current catalyst commentary.
How does Milestone Pharmaceuticals Inc. describe recent progress with Self-Administered?
Patient enrollment in the Phase 3 atrial fibrillation with rapid ventricular rate registration trial is expected to begin in the second half of 2026. The EMA review of the marketing authorization application for etripamil in PSVT is ongoing.
What is Cardiac?
Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions.